Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer's disease.
Tengfei GuoDeniz KormanRenaud La JoieLeslie M ShawJohn Q TrojanowskiWilliam J JagustSusan M Landaunull nullPublished in: Alzheimer's research & therapy (2020)
Together, these findings suggest that CSF pTau/Aβ40 may be a superior measure of tauopathy compared to CSF pTau alone, and CSF pTau/Aβ40 enables detection of tau accumulation at an earlier stage than FTP among Aβ+ individuals.